MNPR · Monopar Therapeutics · Insider Trading

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05-27-2026.

On February 2, 2022, the reporting person was granted stock options to purchase up to 16,280 shares of common stock. The options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter. On July 1, 2024, 6,105 options were forfeited upon Ms. Tsuchimoto's retirement from the Company.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05-27-2026.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05-27-2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.13 to $71.098, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05-27-2026.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05-27-2026.

On August 28, 2018, the reporting person was granted stock options to purchase up to 8,220 shares of common stock. The options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05-27-2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.14 to $71.58, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05-27-2026.

On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter.

On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter.

On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter.

On August 9, 2018, the reporting person was granted stock options to purchase up to 5,220 shares of common stock. The options vest 20% on January 1, 2019, 20% on April 1, 2019, 20% on July 1, 2019, 20% on October 1, 2019 and 20% on January 1, 2020.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05-26-2026.

On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter.

On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.59 to $68.77, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (7) to this Form 4.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05-27-2026.

On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.02 to $70.32, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (7) to this Form 4.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05-27-2026.

On August 28, 2018, the reporting person was granted stock options to purchase up to 8,220 shares of common stock. The options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter.

On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.56 to $66.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (7) to this Form 4.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05-27-2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.88 to $67.57, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (7) to this Form 4.

Represents additional shares withheld by the issuer to pay for the applicable withholding tax due to administrative error in connection with the vesting and settlement of 12,873 restricted stock units on June 30, 2026, as reported on a Form 4 filed July 2, 2026.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.50 to $79.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.50 to $80.01, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.50 to $78.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026.

On February 20, 2017, the reporting person was granted stock options to purchase up to 16,800 shares of common stock. Stock options vest 6/48ths on the six-month anniversary of grant date and 1/48th per month thereafter.

Represents shares acquired on vesting and settlement of restricted stock units.

Represents shares acquired on vesting and settlement of restricted stock units.

On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

Represents shares acquired on vesting and settlement of restricted stock units.

Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

Represents shares acquired on vesting and settlement of restricted stock units.

On December 2, 2025, the reporting person was granted 9,826 restricted stock units, vesting 6/48ths (1,228) on June 30, 2026, and 3/48ths (614 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

Represents shares acquired on vesting and settlement of restricted stock units.

On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

On December 2, 2025, the reporting person was granted 13,919 restricted stock units, vesting 6/48ths (1,740) on June 30, 2026, and 3/48ths (870 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

Represents shares acquired on vesting and settlement of restricted stock units.

Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.56 to $89.91, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.

On August 9, 2018, the reporting person was granted stock options to purchase up to 29,100 shares of common stock. Stock options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.

On February 2, 2022, the reporting person was granted stock options to purchase up to 42,204 shares of common stock. Stock options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.54 to $89.51, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.54 to $87.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.54 to $88.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

On February 2, 2022, the reporting person was granted stock options to purchase up to 16,279 shares of common stock. The options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

On August 28, 2018, the reporting person was granted stock options to purchase up to 8,220 shares of common stock. The options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.